AGC and Medinet sign agreement for cell therapy CDMO business
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
The approval further adds to Biocon’s portfolio of complex drug products
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Nearly 200 participants from 50 Unani Academia and Council participated
Subscribe To Our Newsletter & Stay Updated